ReviewFrontiers in immunology2023
CCHFV vaccine development, current challenges, limitations, and future directions.
Review in Frontiers in immunology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Systematic review and meta-analysis for the occurrence of Crimean-Congo hemorrhagic fever, Tularemia, and Rift Valley fever in pastoralist systems in Africa.Frontiers in veterinary science · 2025Pooled it
- Dual-antigen AdV5 vaccines against Crimean-Congo hemorrhagic fever virus induce superior humoral and Th1-biased cellular immunity.Scientific reports · 2026Article
- Crimean-Congo Hemorrhagic Fever Virus in Africa: Epidemiological Trends, Transmission Ecology, Hotspot Heterogeneity, and Preparedness Challenges-A Narrative Review.Tropical medicine and infectious disease · 2026Review
- Crimean-Congo hemorrhagic fever virus protein GP38 from isolate M18-China confers broad immunological breadth.Research square · 2026Article
- Targeting Crimean-Congo hemorrhagic fever virus: computational and MD-driven discovery of Moringa oleifera peptides against the RdRp-embedded OTU protease.Scientific reports · 2026Article
- In Silico Analysis of Potential Vaccine Antigens for the Treatment of Crimean-Congo Hemorrhagic Fever Virus (Cchfv).Pharmaceutical research · 2026Article
- Modelling tick abundance and environmental suitability in meso-Mediterranean landscapes for the prevention of tick-borne diseases.PLoS neglected tropical diseases · 2025Article
- Review
- Seroprevalence of tick-borne infections in blood donors in Europe: a systematic review.New microbes and new infections · 2025Review
- Single dose VSV-based vaccine protects mice against lethal heterologous Crimean-Congo hemorrhagic fever virus challenge.NPJ vaccines · 2025Article
- Article
- Engineering and structures of Crimean-Congo hemorrhagic fever virus glycoprotein complexes.Cell · 2025Article
- Introduction of Vector-Borne Infections in Europe: Emerging and Re-Emerging Viral Pathogens with Potential Impact on One Health.Pathogens (Basel, Switzerland) · 2025Review
- Advancements in vaccine development and therapeutic approaches for severe fever with Thrombocytopenia Syndrome.Frontiers in cellular and infection microbiology · 2025Review
- Replicating RNA vaccine confers durable immunity against Crimean Congo hemorrhagic fever virus challenge in mice.NPJ vaccines · 2024Article
- Understanding Viral Haemorrhagic Fevers: Virus Diversity, Vector Ecology, and Public Health Strategies.Pathogens (Basel, Switzerland) · 2024Review
- Interventions for the control of Crimean-Congo hemorrhagic fever and tick vectors.NPJ vaccines · 2024Review
- Crimean-Congo hemorrhagic fever cases diagnosed during an outbreak of Sudan virus disease in Uganda, 2022-23.PLoS neglected tropical diseases · 2024Article
- Looking Beyond the Lens of Crimean-Congo Hemorrhagic Fever in Africa.Emerging infectious diseases · 2024Review
- Recent Advances in Crimean-Congo Hemorrhagic Fever Virus Detection, Treatment, and Vaccination: Overview of Current Status and Challenges.Biological procedures online · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Crimean-Congo hemorrhagic fever (CCHF) is the most prevalent tick-borne viral disease affecting humans. The disease is life-threatening in many regions of the developing world, including Africa, Asia, the Middle East, and Southern Europe. In line with the rapidly increasing disease prevalence, various vaccine strategies are under development. Despite a large number of potential vaccine candidates, there are no approved vaccines as of yet. This paper presents a detailed comparative analysis of current efforts to develop vaccines against CCHFV, limitations associated with current efforts, and future research directions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.